2017
The clinical utility of the Medication Adherence Questionnaire (MAQ) in an alcohol pharmacotherapy trial
Zweben A, Piepmeier M, Fucito L, O'Malley S. The clinical utility of the Medication Adherence Questionnaire (MAQ) in an alcohol pharmacotherapy trial. Journal Of Substance Use And Addiction Treatment 2017, 77: 72-78. PMID: 28476276, PMCID: PMC5480370, DOI: 10.1016/j.jsat.2017.04.001.Peer-Reviewed Original ResearchConceptsMedication Adherence QuestionnaireMedication adherenceAdherence QuestionnaireMedical managementTreatment attendanceAlcohol pharmacotherapy trialsAlcohol-dependent smokersTreatment satisfaction ratingsBrief psychosocial treatmentsAlcohol use disorderMM sessionsPharmacology treatmentBaseline characteristicsBaseline demographicsAlcohol pharmacotherapyMedication nonadherenceUnintentional nonadherenceAdherence groupPharmacotherapy trialsDependent smokersTreatment adherenceSingle administrationPatient ratingsTreatment periodClinical utility
2015
Reduction of alcohol drinking in young adults by naltrexone: a double-blind, placebo-controlled, randomized clinical trial of efficacy and safety.
O'Malley SS, Corbin WR, Leeman RF, DeMartini KS, Fucito LM, Ikomi J, Romano DM, Wu R, Toll BA, Sher KJ, Gueorguieva R, Kranzler HR. Reduction of alcohol drinking in young adults by naltrexone: a double-blind, placebo-controlled, randomized clinical trial of efficacy and safety. The Journal Of Clinical Psychiatry 2015, 76: e207-13. PMID: 25742208, PMCID: PMC4442987, DOI: 10.4088/jcp.13m08934.Peer-Reviewed Original ResearchConceptsHeavy drinking daysBlood alcohol concentrationPercent days abstinentDrinking daysNumber of drinksYoung adultsDays abstinentPercent heavy drinking daysOutpatient research centerSafety of naltrexonePlacebo-controlled studySerious adverse eventsRisk-benefit ratioPercentage of daysAdverse eventsSecondary outcomesPrimary outcomeFrequency of drinkingOpioid antagonistAdult heavy drinkersAlcohol drinkingClinical trialsEvaluable samplesYoung adult heavy drinkersTreatment period